Chemical formula: C₂₇H₂₇F₂N₅O₃ Molecular mass: 507.208 g/mol PubChem compound: 118107483
Remibrutinib interacts in the following cases:
It is recommended to monitor patients more frequently for potential adverse reactions when remibrutinib is used with P-glycoprotein (P-gp) substrates and breast-cancer resistance protein (BCRP) substrates with a narrow therapeutic index.
Co-administration of digoxin (a P-gp substrate with a narrow therapeutic index) with remibrutinib led to a 1.4-fold increase in the AUC and a 2.1-fold increase in the Cmax of digoxin. Co-administration of rosuvastatin (a BCRP substrate without a narrow therapeutic index) with remibrutinib led to a 1.7-fold increase in the AUC and a 1.6-fold increase in the Cmax of rosuvastatin.
Concomitant use with moderate or strong CYP3A4 inducers decreases remibrutinib exposure and consequently may decrease the efficacy of remibrutinib. Concomitant use with moderate or strong CYP3A4 inducers must be avoided.
Co-administration of carbamazepine (strong to moderate CYP3A4 inducer) decreased the remibrutinib blood exposure by 74% (Cmax) and 78% (AUC).
Remibrutinib is a substrate of cytochrome P450 enzyme 3A4 (CYP3A4), therefore there is a potential for interaction with other concomitantly administered medicinal products that are metabolised by or modulate the activity of CYP3A4.
In a drug-interaction study, the effect of administration of remibrutinib (100 mg twice daily) on the pharmacokinetics of midazolam (a sensitive CYP3A4 substrate) led to a 43% increase in the AUC and a 27% increase in the Cmax of midazolam. The effect of the clinical dose of remibrutinib (25 mg twice daily) was not studied and may be different. Remibrutinib should not be used with concomitant administration of CYP3A4 substrates that have narrow therapeutic indices (e.g. ciclosporin, tacrolimus, digoxin, warfarin, carbamazepine).
The safety of remibrutinib with live or live-attenuated vaccines has not been studied. Vaccination with live or live-attenuated vaccines is therefore not recommended during treatment with remibrutinib.
The safety of remibrutinib with non-live vaccines has been studied, therefore non-live vaccines can be given during remibrutinib treatment. To optimise the immune response to non-live vaccines, interruption of remibrutinib treatment should be considered (from 1 week prior to the planned vaccination until 2 weeks after the vaccination).
In a placebo-controlled study in healthy volunteers using remibrutinib 100 mg twice daily, the immune response to non-live vaccines was not significantly impacted when remibrutinib was interrupted for 1 week before until 2 weeks after vaccination. However, concomitant remibrutinib treatment was associated with a 60% reduction of responders to the T cell-independent polysaccharide PPV23 vaccine, a 21% reduction in IgG response to keyhole limpet haemocyanin (KLH) vaccine (T cell-dependent neoantigen), comparable response rates (1 to 14% reduction) for 3 out of 4 of the antigens in influenza vaccine (T cell-dependent) and a 27% reduction for 1 out of 4 of the influenza antigens.
Concomitant use with strong CYP3A4 inhibitors increases remibrutinib exposure and consequently may increase the risk for adverse reactions with remibrutinib. Concomitant use with strong CYP3A4 inhibitors must be avoided.
Co-administration of ritonavir, a strong CYP3A4/P-gp inhibitor, led to a 4.3-fold increase in the AUC and a 3.3-fold increase in the Cmax of remibrutinib.
Remibrutinib is not recommended for use in patients with severe hepatic impairment.
Patients receiving antithrombotic agents with remibrutinib may be at an increased risk of bleeding. The risks and benefits of co-administration of antithrombotic agents with remibrutinib must be considered.
It is recommended to interrupt remibrutinib for 3 to 7 days before surgery and for 3 to 7 days after surgery depending upon the type of surgery and the risk of bleeding.
There are limited data from the use of remibrutinib in pregnant women. Studies in animals have shown reproductive toxicity. Remibrutinib is not recommended during pregnancy.
It is unknown whether remibrutinib/metabolites are excreted in human milk. A risk to the newborns/infants cannot be excluded. Breast-feeding should be discontinued during treatment with remibrutinib and for 1 week after the last dose.
Sexually active women of childbearing potential must use effective contraception (methods that result in less than 1% pregnancy rates) during remibrutinib treatment and for at least 1 week after the last dose. Women of childbearing potential must be advised that animal studies have shown remibrutinib to be harmful to the developing foetus.
There are no data on the effect of remibrutinib on human fertility. No adverse effects on fertility were observed in male and female rats.
Remibrutinib has no or negligible influence on the ability to drive and use machines.
The most frequently reported adverse reaction is upper respiratory tract infections (14.7%) such as nasopharyngitis (6.6%) and influenza (2.5%).
Adverse reactions are listed according to MedDRA system organ class. Within each system organ class, the adverse reactions are ranked by frequency, with the most frequent reactions first. In addition, the corresponding frequency category for each adverse reaction is defined as: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1 000 to <1/100); rare (≥1/10 000 to <1/1 000); very rare (<1/10 000); not known (cannot be estimated from available data).
Table 1. Adverse reactions*:
| System organ class | Adverse reaction | Frequency |
| Infections and infestations | Upper respiratory tract infections1 | Very common |
| Herpes virus infections2 | Common | |
| Nervous system disorders | Headache | Common |
| Vascular disorders | Bruising Petechiae Contusion3 Ecchymosis Purpura | Common Common Common Common Uncommon |
| Bleeding Haematuria Epistaxis Conjunctival bleeding Gingival bleeding | Common Common Uncommon Uncommon Uncommon | |
| Gastrointestinal disorders | Nausea | Common |
| Abdominal pain | Common | |
| Musculoskeletal and connective tissue disorders | Back pain | Common |
| General disorders and administration site conditions | Pyrexia | Common |
* 24-week placebo-controlled phase III studies in CSU
1 Upper respiratory tract infections include preferred terms: upper respiratory tract infection, acute sinusitis, chronic sinusitis, H1N1 influenza, influenza, laryngitis, nasopharyngitis, pharyngitis, pharyngitis streptococcal, pharyngotonsillitis, rhinitis, sinusitis, tonsillitis, tonsillitis bacterial, upper respiratory tract infection bacterial, upper respiratory tract infection viral
2 Herpes virus infections include preferred terms: herpes simplex, herpes zoster, oral herpes
3 Contusion includes preferred terms: contusion, increased tendency to bruise, haematoma
The safety profile of remibrutinib in patients treated for up to 52 weeks in REMIX-1 and REMIX-2 remained consistent with the adverse reactions reported in Table 1.
In the 24-week placebo-controlled, double-blind treatment period of the pooled dataset (REMIX-1 and REMIX-2 phase III studies), mucocutaneous bleeding events (listed in Table 1 under "Vascular disorders") occurred in 7.8% of patients treated with remibrutinib. The most frequently reported events were bruising-related: petechiae (3.8%) and contusion (2.3%). Overall, in patients treated with remibrutinib, 92.0% of these events were mild and 8.0% were moderate in severity. The median time to onset was 25 days and the median duration was 22 days. All cases resolved spontaneously without additional treatment. No association between mucocutaneous bleeding events and low platelet counts was observed. Co-administration of remibrutinib with anticoagulants was not allowed in clinical studies, but co-administration with antiplatelet agents (acetylsalicylic acid (≤100 mg/day) or clopidogrel (≤75 mg/day)) was permitted.
In patients treated with remibrutinib, 0.5% experienced mucocutaneous bleeding events that led to remibrutinib discontinuation and 1.0% led to remibrutinib interruption.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.